GlassScriptPhysician profile
Jacqualine Gervais
NPI 1336481803
$29,354.23
in general payments reported to CMS, 2019-2025
9 companies · $8,511 in 2025
The $8,511 reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $149 · 2023: $17K · 2024: $4,089 · 2025: $8,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $4,096 · Food and Beverage: $1,672 · Education: $12.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,425.00 |
| Travel and Lodging | $4,096.24 |
| Food and Beverage | $1,671.73 |
| Education | $12.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $28,210.14 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $516.46 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Axsome Therapeutics, INC. | $378.34 | 2023-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $92.57 | 2024 | Fanapt |
| Alkermes, INC. | $66.31 | 2023-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $33.13 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $21.35 | 2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.00 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $15.93 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqualine Gervais listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.